查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1556568

腫瘤微環境市場報告：2030 年趨勢、預測與競爭分析

Tumor Microenvironment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

腫瘤微環境趨勢與預測

預計2024年至2030年全球腫瘤微環境市場將以11.2%的複合年成長率成長。該市場的主要驅動力是癌症發病率上升、腫瘤微環境在免疫腫瘤學中的重要性日益增加以及政府和製藥公司對腫瘤學研究的投資增加。全球腫瘤微環境市場前景廣闊，生物製藥公司、醫院、診斷實驗室、研究機構和CRO市場充滿機會。

按部位分類的腫瘤微環境

這項研究提供了按癌症類型、產品、治療方法、最終用途和區域分類的全球腫瘤微環境的預測。

腫瘤微環境市場洞察

Lucintel 預測，在預測期內，肺癌仍將是最大的細分市場。

生物製藥公司仍然是市場上最大的部分。

由於尖端技術的採用增加、政府對生命科學研究的資助以及大型製藥企業的存在，北美可能仍將是最大的地區。

常問問題

Q1.市場成長預測是多少：

A1. 2024年至2030年，全球腫瘤微環境市場預計將以11.2%的複合年成長率成長。

Q2. 影響市場成長的關鍵促進因素是：

A2. 這個市場的主要驅動力是癌症盛行率的上升、腫瘤微環境在免疫腫瘤學中日益重要，以及政府和製藥公司對腫瘤學研究的投資不斷增加。

Q3.市場的主要細分市場是：

A3. 全球腫瘤微環境市場前景廣闊，生物製藥公司、醫院、診斷實驗室、研究機構和CRO市場充滿機會。

Q4.市場的主要企業是：

A4.主要腫瘤微環境公司如下：

  • Thermo Fisher Scientific
  • Illumina
  • Danaher
  • Merck
  • BD Biosciences
  • Promega
  • Bio-Techne
  • Bio-Rad Laboratories
  • Hoffmann-La Roche
  • QIAGEN

Q5.未來最大的細分市場是什麼？

A5.Lucintel 預計肺癌在預測期內仍將是其最大的細分市場。

Q6.未來五年預計哪些地區的市場成長最大？

A6. 由於尖端技術的採用增加、政府對生命科學研究的資助以及大型製藥企業的存在，預計北美仍將是最大的地區。

Q7. 可以客製化報告嗎？

A7。

目錄

第1章執行摘要

第2章全球腫瘤微環境市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球腫瘤微環境市場趨勢（2018-2023）與預測（2024-2030）
  • 按癌症類型分類的全球腫瘤微環境市場
    • 肺癌
    • 大腸直腸癌
    • 乳癌
    • 攝護腺癌
    • 膀胱癌
    • 其他
  • 按產品分類的腫瘤微環境市場
    • T細胞
    • 腫瘤相關巨噬細胞
    • 骨髓源性抑制細胞
    • 癌症相關纖維母細胞
    • 調節性T細胞
    • 其他
  • 按治療方法的腫瘤微環境市場
    • 單株抗體
    • 細胞激素
    • 癌症疫苗
    • 溶瘤病毒
    • 過繼性細胞療法
    • 其他
  • 按最終用途分類的全球腫瘤微環境市場
    • 生物製藥公司
    • 醫院
    • 診斷實驗室
    • 調查機構
    • CRO（藥物委外研發機構）
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球腫瘤微環境市場：按地區
  • 北美腫瘤微環境市場
  • 歐洲腫瘤微環境市場
  • 亞太腫瘤微環境市場
  • 其他地區腫瘤微環境市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按癌症類型分類的全球腫瘤微環境市場成長機會
    • 按產品分類的全球腫瘤微環境市場成長機會
    • 按治療方法方式分類的全球腫瘤微環境市場成長機會
    • 全球腫瘤微環境市場成長機會（依最終用途）
    • 按地區分類的全球腫瘤微環境市場成長機會
  • 全球腫瘤微環境市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 全球腫瘤微環境市場的產能擴張
    • 全球腫瘤微環境市場的併購與合資
    • 認證和許可

第7章主要企業概況

  • Thermo Fisher Scientific
  • Illumina
  • Danaher
  • Merck
  • BD Biosciences
  • Promega
  • Bio-Techne
  • Bio-Rad Laboratories
  • Hoffmann-La Roche
  • QIAGEN
簡介目錄

Tumor Microenvironment Trends and Forecast

The future of the global tumor microenvironment market looks promising with opportunities in the biopharmaceutical company, hospital, diagnostic laboratory, research institute, and contract research organization markets. The global tumor microenvironment market is expected to grow with a CAGR of 11.2% from 2024 to 2030. The major drivers for this market are rising prevalence of cancer, emerging importance of the tumor microenvironment in immuno-oncology, along with the governments and pharmaceutical corporations boosting their investments in oncology research.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Tumor Microenvironment by Segment

The study includes a forecast for the global tumor microenvironment by cancer type, product, therapy, end use, and region.

Tumor Microenvironment Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Bladder Cancer
  • Others

Tumor Microenvironment Market by Product [Shipment Analysis by Value from 2018 to 2030]:

  • T Cells
  • Tumor-Associated Macrophages
  • Myeloid-Derived Suppressor Cells
  • Cancer-Associated Fibroblasts
  • Regulatory T Cells
  • Others

Tumor Microenvironment Market by Therapy [Shipment Analysis by Value from 2018 to 2030]:

  • Monoclonal Antibodies
  • Cytokines
  • Cancer Vaccines
  • Oncolytic Viruses
  • Adoptive Cell Therapies
  • Others

Tumor Microenvironment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Biopharmaceutical Companies
  • Hospital
  • Diagnostic Laboratories
  • Research Institutes
  • Contract Research Organizations
  • Others

Tumor Microenvironment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Tumor Microenvironment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies tumor microenvironment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the tumor microenvironment companies profiled in this report include-

  • Thermo Fisher Scientific
  • Illumina
  • Danaher
  • Merck
  • BD Biosciences
  • Promega
  • Bio-Techne
  • Bio-Rad Laboratories
  • Hoffmann-La Roche
  • QIAGEN

Tumor Microenvironment Market Insights

Lucintel forecasts that lung cancer will remain the largest segment over the forecast period.

Within this market, biopharmaceutical company will remain the largest segment.

North America will remain the largest region over the forecast period due to high adoption of modern technology, funding from the government for life science research, and the presence of big pharmaceutical and biotech corporations in the region.

Features of the Global Tumor Microenvironment Market

Market Size Estimates: Tumor microenvironment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Tumor microenvironment market size by cancer type, product, therapy, end use, and region in terms of value ($B).

Regional Analysis: Tumor microenvironment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different cancer type, product, therapy, end use, and regions for the tumor microenvironment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the tumor microenvironment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for tumor microenvironment market?

Answer: The global tumor microenvironment market is expected to grow with a CAGR of 11.2% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the tumor microenvironment market?

Answer: The major drivers for this market are rising prevalence of cancer, emerging importance of the tumor microenvironment in immuno-oncology, along with the governments and pharmaceutical corporations boosting their investments in oncology research.

Q3. What are the major segments for tumor microenvironment market?

Answer: The future of the global tumor microenvironment market looks promising with opportunities in the biopharmaceutical company, hospital, diagnostic laboratory, research institute, and contract research organization markets.

Q4. Who are the key tumor microenvironment market companies?

Answer: Some of the key tumor microenvironment companies are as follows:

  • Thermo Fisher Scientific
  • Illumina
  • Danaher
  • Merck
  • BD Biosciences
  • Promega
  • Bio-Techne
  • Bio-Rad Laboratories
  • Hoffmann-La Roche
  • QIAGEN

Q5. Which tumor microenvironment market segment will be the largest in future?

Answer: Lucintel forecasts that lung cancer will remain the largest segment over the forecast period.

Q6. In tumor microenvironment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high adoption of modern technology, funding from the government for life science research, and the presence of big pharmaceutical and biotech corporations in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the tumor microenvironment market by cancer type (lung cancer, colorectal cancer, breast cancer, prostate cancer, bladder cancer, and others), product (T cells, tumor-associated macrophages, myeloid-derived suppressor cells, cancer-associated fibroblasts, regulatory t cells, and others), therapy (monoclonal antibodies, cytokines, cancer vaccines, oncolytic viruses, adoptive cell therapies, and others), end use (biopharmaceutical companies, hospital, diagnostic laboratories, research institutes, contract research organizations, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Tumor Microenvironment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Tumor Microenvironment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Tumor Microenvironment Market by Cancer Type
    • 3.3.1: Lung Cancer
    • 3.3.2: Colorectal Cancer
    • 3.3.3: Breast Cancer
    • 3.3.4: Prostate Cancer
    • 3.3.5: Bladder Cancer
    • 3.3.6: Others
  • 3.4: Global Tumor Microenvironment Market by Product
    • 3.4.1: T Cells
    • 3.4.2: Tumor-Associated Macrophages
    • 3.4.3: Myeloid-Derived Suppressor Cells
    • 3.4.4: Cancer-Associated Fibroblasts
    • 3.4.5: Regulatory T Cells
    • 3.4.6: Others
  • 3.5: Global Tumor Microenvironment Market by Therapy
    • 3.5.1: Monoclonal Antibodies
    • 3.5.2: Cytokines
    • 3.5.3: Cancer Vaccines
    • 3.5.4: Oncolytic Viruses
    • 3.5.5: Adoptive Cell Therapies
    • 3.5.6: Others
  • 3.6: Global Tumor Microenvironment Market by End Use
    • 3.6.1: Biopharmaceutical Companies
    • 3.6.2: Hospital
    • 3.6.3: Diagnostic Laboratories
    • 3.6.4: Research Institutes
    • 3.6.5: Contract Research Organizations
    • 3.6.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Tumor Microenvironment Market by Region
  • 4.2: North American Tumor Microenvironment Market
    • 4.2.1: North American Tumor Microenvironment Market by Cancer Type: Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Bladder Cancer, and Others
    • 4.2.2: North American Tumor Microenvironment Market by End Use: Biopharmaceutical Companies, Hospital, Diagnostic Laboratories, Research Institutes, Contract Research Organizations, and Others
  • 4.3: European Tumor Microenvironment Market
    • 4.3.1: European Tumor Microenvironment Market by Cancer Type: Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Bladder Cancer, and Others
    • 4.3.2: European Tumor Microenvironment Market by End Use: Biopharmaceutical Companies, Hospital, Diagnostic Laboratories, Research Institutes, Contract Research Organizations, and Others
  • 4.4: APAC Tumor Microenvironment Market
    • 4.4.1: APAC Tumor Microenvironment Market by Cancer Type: Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Bladder Cancer, and Others
    • 4.4.2: APAC Tumor Microenvironment Market by End Use: Biopharmaceutical Companies, Hospital, Diagnostic Laboratories, Research Institutes, Contract Research Organizations, and Others
  • 4.5: ROW Tumor Microenvironment Market
    • 4.5.1: ROW Tumor Microenvironment Market by Cancer Type: Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Bladder Cancer, and Others
    • 4.5.2: ROW Tumor Microenvironment Market by End Use: Biopharmaceutical Companies, Hospital, Diagnostic Laboratories, Research Institutes, Contract Research Organizations, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Tumor Microenvironment Market by Cancer Type
    • 6.1.2: Growth Opportunities for the Global Tumor Microenvironment Market by Product
    • 6.1.3: Growth Opportunities for the Global Tumor Microenvironment Market by Therapy
    • 6.1.4: Growth Opportunities for the Global Tumor Microenvironment Market by End Use
    • 6.1.5: Growth Opportunities for the Global Tumor Microenvironment Market by Region
  • 6.2: Emerging Trends in the Global Tumor Microenvironment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Tumor Microenvironment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Tumor Microenvironment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Thermo Fisher Scientific
  • 7.2: Illumina
  • 7.3: Danaher
  • 7.4: Merck
  • 7.5: BD Biosciences
  • 7.6: Promega
  • 7.7: Bio-Techne
  • 7.8: Bio-Rad Laboratories
  • 7.9: Hoffmann-La Roche
  • 7.10: QIAGEN